Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection
Journal of the Royal Society Interface · 2026
DOI: 10.1098/rsif.2025.1018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Royal Society Interface, 2026. Verfasst von Clare McCormack und 12 weiteren Autor:innen. Beteiligte Einrichtung: MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK. Hauptthemen laut MEDLINE: Dengue Virus, Dengue, Antiviral Agents, Virus Replication. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Almost half of the world's population is at risk of acquiring dengue virus (DENV) each year. However, no specific licensed prophylactic or antiviral treatment for dengue currently exists. Mosnodenvir, a novel DENV inhibitor, has been shown to inhibit DENV replication in vitro and in animal studies. Here, we provide new insights into the in vivo prophylactic inhibitory effect of mosnodenvir exposure on primary DENV-2 infection by fitting mechanistic within-host models of DENV infection to virological and serological data observed from pre-clinical challenge studies in AG129 mice and rhesus macaques. We estimated a median mosnodenvir concentration achieving 50% of maximal inhibitory effect (IC50) on viral replication of 8.35 (6.82, 9.22) ng ml−1 and 7.61 (5.67, 8.92) ng ml−1 for AG129 mice and rhesus macaques, respectively. A higher concentration is typically required to suppress viral replication in AG129 mice compared with rhesus macaques owing to a higher estimated within-host basic reproduction number (R0) in mice. By integrating multiple data types in a single framework, this study enhances our understanding of the within-host dynamics of primary DENV infection in non-human host species. Furthermore, the methods developed here could possibly assist in quantifying the prophylactic inhibitory effect of mosnodenvir on DENV infections in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MRC Centre for Global Infectious Disease Analysis, Imperial College London, London, UK.
- Johnson and Johnson Pharmaceutical Research and Development Belgium , Beerse, Flanders, Belgium.
- Biomedical Primate Research Centre , Rijswijk, ZH, The Netherlands.
- Virology, Antiviral Drug & Vaccine Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute of Medical Research, KU, Leuven, Belgium.
ORCID-Profile: Clare McCormack, Nele Goeyvaerts
Zitieren
APA
McCormack, C., Goethals, O., Goeyvaerts, N., De Trixhe, X. W., Verstrepen, B., van Wesenbeek, L., Verschoor, E., Kaptein, S. J., Neyts, J., Van Loock, M., Ferguson, N., Ackaert, O., & Dorigatti, I. (2026). Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection. Journal of the Royal Society Interface. https://doi.org/10.1098/rsif.2025.1018
Vancouver
McCormack C, Goethals O, Goeyvaerts N, De Trixhe XW, Verstrepen B, van Wesenbeek L, et al. Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection. Journal of the Royal Society Interface. 2026. doi:10.1098/rsif.2025.1018
BibTeX
@article{McCormack2026,
author = {McCormack, Clare and Goethals, Olivia and Goeyvaerts, Nele and De Trixhe, Xavier Woot and Verstrepen, Babs and van Wesenbeek, Liesbeth and Verschoor, Ernst and Kaptein, Suzanne J and Neyts, Johan and Van Loock, Marnix and Ferguson, Neil and Ackaert, Oliver and Dorigatti, Ilaria},
title = {Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection},
journal = {Journal of the Royal Society Interface},
year = {2026},
doi = {10.1098/rsif.2025.1018}
}
EUVIMED